At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 150 enrolled
Drug / intervention
GSK1247446A Group +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Immunogenicity, Safety and Reactogenicity of Adjuvanted Influenza Vaccine Candidate Compared to Fluarix™ (GlaxoSmithKline Biologicals) Administered Intramuscularly in Elderly Aged 60 Years and Older.
In Brief
A Phase 2 clinical trial evaluating GSK1247446A Group and Fluarix™ for Influenza. Completed, enrolled 150 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the immunogenicity and the safety of the candidate vaccine compared to Fluarix™ administered intramuscularly in elderly aged 60 years and above
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesBelgium
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2006
Enrollment StartOct 2006
Primary CompletionNov 2006
Study CompletionNov 2006
TodayJul 2026
First PostedAug 15, 2006
Enrollment StartOct 2, 2006
Primary CompletionNov 1, 2006
Study CompletionNov 17, 2006
TodayJul 2, 2026
Enrollment to primary: 29 daysPosted 19.9 years ago
Interventions
GSK1247446A Groupbiological
Low dose influenza vaccine adjuvanted with AS03 compared
Fluarix™biological
GlaxoSmithKline (GSK) Biologicals' inactivated influenza split vaccine.